Changes for page Neurodiagnoses
Last modified by manuelmenendez on 2025/03/03 22:46
From version 29.1
edited by manuelmenendez
on 2025/01/29 18:52
on 2025/01/29 18:52
Change comment:
There is no comment for this version
To version 16.1
edited by manuelmenendez
on 2025/01/28 00:00
on 2025/01/28 00:00
Change comment:
There is no comment for this version
Summary
-
Page properties (1 modified, 0 added, 0 removed)
Details
- Page properties
-
- Content
-
... ... @@ -2,9 +2,9 @@ 2 2 ((( 3 3 (% class="container" %) 4 4 ((( 5 -= //A new tridimensional diagnostic framework for CNS dis eases// =5 += //A new tridimensional diagnostic framework for CNS conditions// = 6 6 7 -This project is focused on developing a novel nosological and diagnostic framework for CNSdiseases by using advanced AI techniques and integrating data from neuroimaging, biomarkers, and biomedical ontologies.7 +This project is focused on developing a novel nosological and diagnostic framework for neurological diseases by using advanced AI techniques and integrating data from neuroimaging, biomarkers, and biomedical ontologies. 8 8 We aim to create a structured, interpretable, and scalable diagnostic tool. 9 9 ))) 10 10 ))) ... ... @@ -15,18 +15,17 @@ 15 15 ((( 16 16 = What is this about and what can I find here? = 17 17 18 -= **Overview** = 18 +== **Overview** == 19 19 20 -The classification and diagnosis of central nervous system (CNS) diseases have long been constrainedby traditional phenotypic approaches that fail to capture the underlying pathophysiologicalmechanisms, molecular biomarkers, and neuroanatomicalchanges that drive disease progression. As neurodegenerative and psychiatricdisorders exhibit significant clinical overlap, co-pathology, and heterogeneity, a new diagnostic frameworkis urgently needed—onethatshiftsfromsymptom-basedclassifications towardan etiology-driven,tridimensionalsystemintegrating genetics, proteomics,neuroimaging, andcomputationalmodeling. By leveraging AI, multi-modal biomarkers, and precision medicine, thisframework aims to providea more objective, scalable, and biologicallygrounded approach to diagnosingand managing CNS diseases, ultimately leading toearlier detection, personalized interventions, and improved patient outcomes.20 +The //Tridimensional Diagnostic Framework// redefines how CNS conditions are classified by focusing on: 21 21 22 -The project aims to develop a tridimensional diagnostic framework with an AI-powered annotation system, integrating etiology, molecular biomarkers, and neuroanatomoclinical correlations for precise and scalable CNS disease diagnostics. 23 - 24 -The //Tridimensional Diagnostic Framework// redefines CNS diseases can be classified and diagnosed by focusing on: 25 - 26 26 * **Axis 1**: Etiology (genetic or other causes of diseases). 27 27 * **Axis 2**: Molecular Markers (biomarkers). 28 28 * **Axis 3**: Neuroanatomoclinical correlations (linking clinical symptoms to structural changes in the nervous system). 29 29 26 +[[Neurodegenerative diseases can be studied and classified in a tridimensional scheme with three axes: anatomic–clinical, molecular, and etiologic. CSF, cerebrospinal fluid; FDG, fluorodeoxyglucose; MRI, magnetic resonance imaging; PET, positron emission tomography.>>image:tridimensional.png||alt="tridimensional view of neurodegenerative diseases"]] 27 + 28 + 30 30 This methodology enables: 31 31 32 32 * Greater precision in diagnosis. ... ... @@ -33,18 +33,14 @@ 33 33 * Integration of incomplete datasets using AI-driven probabilistic modeling. 34 34 * Stratification of patients for personalized treatment. 35 35 36 -== ** The case of neurodegenerativediseases** ==35 +== **Diagnostic Axes** == 37 37 38 -There have been described these 3 diagnostic axes: 39 - 40 -[[Neurodegenerative diseases can be studied and classified in a tridimensional scheme with three axes: anatomic–clinical, molecular, and etiologic. CSF, cerebrospinal fluid; FDG, fluorodeoxyglucose; MRI, magnetic resonance imaging; PET, positron emission tomography.>>image:tridimensional.png||alt="tridimensional view of neurodegenerative diseases"]] 41 - 42 42 * ((( 43 43 **Axis 1: Etiology** 44 44 45 45 * //Description//: Focuses on genetic and sporadic causes, identifying risk factors and potential triggers. 46 46 * //Examples//: APOE ε4 as a genetic risk factor, or cardiovascular health affecting NDD progression. 47 -* //Tests//: Genetic testing, lifestyle ,and cardiovascular screening.42 +* //Tests//: Genetic testing, lifestyle and cardiovascular screening. 48 48 ))) 49 49 * ((( 50 50 **Axis 2: Molecular Markers** ... ... @@ -86,9 +86,6 @@ 86 86 ))) 87 87 88 88 89 - 90 - 91 - 92 92 (% class="col-xs-12 col-sm-4" %) 93 93 ((( 94 94 {{box title="**Contents**"}} ... ... @@ -101,8 +101,5 @@ 101 101 * `/code`: Machine learning pipelines and scripts. 102 102 * `/data`: Sample datasets for testing. 103 103 * `/outputs`: Generated models, visualizations, and reports. 104 -* [[Methodology>>url:https://wiki.ebrains.eu/bin/view/Collabs/neurodiagnoses/Methodology/]] 105 -* [[Results>>url:https://wiki.ebrains.eu/bin/view/Collabs/neurodiagnoses/Results/]] 106 -* [[to-do-list>>to-do-list]] 107 107 ))) 108 108 )))